New PLK4 Inhibitors Show Potential Against Cancer
Experimental drugs may eventually offer a new treatment path for patients with specific tumor genetic profiles.
Updated on Oct. 31, 2026 in Cancer
Live Poll
Do you trust that new lab research into cancer treatments will lead to real-world patient benefits?
Researchers have characterized two new experimental PLK4 inhibitors, EXEL-0667 and EXEL-1855, which show potential in targeting specific tumor types. These findings offer a new potential approach for treating cancers with near-euploid genomes and wild-type TP53.
Why it matters
Identifying these inhibitors could broaden the scope of targeted cancer therapies, potentially moving treatment beyond cases involving specific gene amplifications like TRIM37. This research helps clarify how genomic stability might dictate a patient's response to future drugs.
This preclinical research involved characterization of two PLK4 inhibitors, EXEL-0667 and EXEL-1855, using in vitro viability assays and in vivo mouse xenograft models. Findings indicate that near-euploid tumor models with wild-type TP53 are particularly sensitive to these inhibitors.
The players
EXEL-0667 and EXEL-1855
These are investigational PLK4 inhibitors currently being studied for their ability to disrupt cancer cell division.
The details
The inhibitors work by targeting PLK4, an enzyme responsible for centriole biogenesis, which is essential for cell division. Partial inhibition of PLK4 leads to centrosome amplification, a process that can disrupt the survival of specific tumor cells. Researchers found that cells with high levels of the protein TRIM37, as well as those with intact TP53 and stable, near-euploid genomes, are most vulnerable to this disruption.
Timeline
The research findings were published on October 31, 2026.
Health Landscape
This development represents a shift toward more nuanced, precision-based approaches to inhibiting tumor growth mechanisms. It builds upon the broader effort to identify predictive biomarkers that help prioritize which patients might benefit from novel targeted therapies.
These results are strictly preclinical and do not yet impact current treatment standards for patients. If you are participating in a clinical trial or monitoring new cancer research, discuss the relevance of genomic testing and emerging biomarker-driven therapies with your oncologist.
The takeaway
Targeting PLK4 enzymes could provide a new way to disrupt the division of cancer cells that lack major genomic mutations. Keep track of updates regarding how genomic tumor profiling continues to shape the future of personalized oncology care.
Further reading
Learn more about the latest developments in precision treatments in our Cancer section.
More information
Review the full findings in the peer-reviewed research article.
Source note: This article includes information reported by Nature.
Live Poll
Do you trust that new lab research into cancer treatments will lead to real-world patient benefits?
